局部进展性肾癌综合治疗的研究进展

王琦; 于德新

局部进展性肾癌综合治疗的研究进展

王琦,
于德新^,

- 安徽医科大学第二附属医院泌尿外科(合肥, 230032)

详细信息

通讯作者: 于德新,E-mail:yudx_urology@yahoo.com.cn

中图分类号: R737.11

收稿日期: 2012-02-11

Corresponding author: , E-mail: yudx_urology@yahoo.com.cn

Received Date: 11 February 2012

摘要

摘要: 局部进展性肾癌的综合治疗包括外科治疗和术后辅助治疗两大类，后者又分为免疫治疗、靶向治疗以及联合治疗等。近年来针对其综合治疗方案的研究不断取得进展，本文对此作一综述。
- 肾癌 /
- 综合治疗

HTML全文

参考文献(33)

[1]	KIM S P, ALT A L, WEIGHT C J, et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma:results from a large, single institution cohort[J]. Urology, 2011, 185(6):2035-2039.
[2]	BILLIA M, VOLPE A, TERRONE C. The current TNM staging system of renal cell carcinoma:arefurther improvements needed[J]? Arch Esp Urol, 2011, 64(10):929-937.
[3]	ANDERSON C B, CLARK P E, MORGAN T M, et al. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma[J]. Urology, 2011, 78(1):99-104.
[4]	SFOUNGARISTOS S, GIANNITSAS K, PERIMENIS P. Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma[J]. Expert Opin Pharmacother, 2011,12(4):533-547.
[5]	ITO H, MAKIYAMA K, KAWAHARA T, et al. Retroperitoneoscopic radical nephrectomy with a small incision for renal cell carcinoma:Comparison with the conventional method[J]. J Negat Results Biomed, 2011,10:11.
[6]	VASDEV N, HUSSEIN H K, DAVIDSON A. Radical renal surgery (laparoscopic and open) in octogenarians[J]. Surgeon, 2011, 9(3):135-141.
[7]	CAPITANIO U, BECKER F, BLUTE M L, et al. Lymph node dissection in renal cell carcinoma[J]. Eur Urol, 2011, 60(6):1212-1220.
[8]	WHITSON J M, HARRIS C R, REESE A C, et al. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases[J]. Urology, 2011,185(5):1615-1620.
[9]	MARTINEZ-SALAMANCA J I, HUANG W C, MILLAN I, et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension[J]. Eur Urol, 2011, 59(1):120-127.
[10]	GARCIA-FADRIQUE G, BUDIA-ALBA A, RUIZ-CERDA J L, et al. Prognostic value of venous tumor thrombus in renal cell carcinoma[J]. Actas Urol Esp, 2012, 36(1):29-34.
[11]	BERTINI R, ROSCIGNO M, FRESCHI M, et al. Impact of venous tumour thrombus consistency(solid vs friable) on cancer-specific survival in patients with renal cell carcinoma[J]. Eur Urol, 2011, 60(2):358-365.
[12]	BOORJIAN S A, SENGUPTA S, BLUTE M L, et al. Renal cell carcinoma:vena caval involvement[J]. BJU Int, 2007, 99(5):1239-1244.
[13]	WEIN A J, KAVOUSSI L R, NOVICK A C, et al. Campbell-Walsh urology[M]. 9th edition Philadelphia. PA:Saunders, 2007:table 47-1515.
[14]	METCALFE C, CHANG-KIT L, DUMITRU I, et al. Antegrade balloon occlusion of inferior vena cava during thrombectomy for renal cell carcinoma[J]. Can Urol Assoc J, 2010, 4(4):105-108.
[15]	CHAVES PORTELA S, SANTOS-ARRONTES D, FERN?NDEZ-ACENERO M J, et al. Stage pT_3a of renal clear cell carcinoma:do tumors with sinus fat involvement behave the same as those with perinephric fat involvement[J]? Rom J Morphol Embryol, 2011, 52(2):569-574.
[16]	TAKAYAMA T, SUGIYAMA T, KAI F, et al. Should ipsilateral solitary adrenal involvement in renal cell carcinoma be staged as M1[J]? Jpn J Clin Oncol, 2011, 41(6):792-796.
[17]	ITO K, NAKAZAWA H, MARUMO K, et al. Risk factors for ipsilateral adrenal involvement in renal cell carcinoma[J]. Urology, 2008,72(2):354-358.
[18]	WEIGHT C J, KIM S P, LOHSE C M, et al. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland[J]. Eur Urol, 2011, 60(3):458-464.
[19]	KOMAI Y, FUJII Y, KIJIMA T, et al. Significance of ipsilateral adrenalectomy in surgery for renal cell carcinoma[J]. Nihon Hinyokika Gakkai Zasshi, 2010, 101(4):592-596.
[20]	FICARRA V, IAFRATE M, CAPPELLARO L, et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT_3-4) renal cell carcinoma according to the cancer-related outcome[J]. Eur Urol, 2007, 51(3):722-729.
[21]	GEORGE S, PILI R, CARDUCCI M A. Role of immunotherapy for renal cell cancer in 2011[J]. J Natl Compr Canc Netw, 2011, 9(9):1011-1018.
[22]	MCDERMOTT D F. Immunotherapy and targeted therapy combinations in renal cancer[J].Curr Clin Pharmacol, 2011, 6(3):207-213.
[23]	LASCHOS K A, PAPAZISIS K T, KONTOVINIS L F, et al. Targeted treatment for metastatic renal cell carcinoma and immune regulation[J]. J BUON, 2010, 15(2):235-240.
[24]	BARRIERE J, HOCH B, FERRERO J M. New perspectives in the treatment of metastatic renal cell carcinoma[J]. Crit Rev Oncol Hematol, 2011 Nov 16.[Epub ahead of print].
[25]	CHOUEIRI M, TANNIR N, JONASCH E. Adjuvant and neoadjuvant therapy in renal cell carcinoma[J]. Curr Clin Pharmacol, 2011,6(3):144-150.
[26]	LIU F, CHEN X, PENG E, et al. VEGF Pathway-targeted therapy for advanced renal cell carcinoma:A meta-analysis of randomized controlled trials[J]. J Huazhong Univ Sci Technolog Med Sci, 2011,31(6):799-806.
[27]	SANTOS N, WENGER J B, HAVRE P, et al. Combination therapy for renal cell cancer:what are possible options[J]? Oncology, 2011, 81(3-4):220-229.
[28]	KOC G, WANG X, LUO Y. Pazopanib:an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma[J]. Can J Urol, 2011, 18(6):5991-5997.
[29]	GROENEWEGEN G, WALRAVEN M, VERMAAT J, et al. Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma[J]. Br J Cancer,2012,106(2):284-289.
[30]	JONASCH E, TANNIR N M. Targeted therapy for locally advanced renal cell carcinoma[J]. Target Oncol, 2010,5(2):113-118.
[31]	GRIVAS P D, REDMAN B G. Immunotherapy of kidney cancer[J]. Curr Clin Pharmacol, 2011, 6(3):151-163.
[32]	JEPPESEN A N, JENSEN H K, DONSKOV F, et al. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma[J]. Br J Cancer, 2010, 102(5):867-872.
[33]	AKAZA H, TSUKAMOTOT, FUJIOKAT, et al. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma:survival benefit for selected patients with lung metastasis and serum sodium level[J]. Jpn J Clin Oncol, 2011, 41(8):1023-1030.